RecruitingPhase 2NCT06991114
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Studying Diffuse cutaneous systemic sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Artiva Biotherapeutics, Inc.
- Principal Investigator
- Michael Saddekni, M.D., PgDip, BCMASArtiva Therapeutics
- Intervention
- Allogeneic NK Cells(drug)
- Enrollment
- 90 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (25)
- Artiva Investigational Site Tuscaloosa, Tuscaloosa, Alabama, United States
- Artiva Investigational Site Phoenix, Phoenix, Arizona, United States
- Artiva Investigational Site Covina, Covina, California, United States
- Artiva Investigational Site Los Alamitos, Los Alamitos, California, United States
- Artiva Investigational Site Aventura, Aventura, Florida, United States
- Artiva Investigational Site Jupiter, Jupiter, Florida, United States
- Artiva Investigational Site Plantation, Plantation, Florida, United States
- Artiva Investigational Site Willowbrook, Willowbrook, Illinois, United States
- Artiva Investigational Site Iowa, Iowa City, Iowa, United States
- Artiva Investigational Site Charlotte, Charlotte, North Carolina, United States
- Artiva Investigational Site Hixson, Hixson, Tennessee, United States
- Artiva Investigational Site Arlington, Arlington, Texas, United States
- Artiva Investigational Site Katy, Katy, Texas, United States
- Artiva Investigational Site Mesquite, Mesquite, Texas, United States
- Artiva Investigational Site Woodland, Woodland, Texas, United States
- +10 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06991114 on ClinicalTrials.govOther trials for Diffuse cutaneous systemic sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07473154Controlling Hyperactive Immunity With Long-lived LymphocytesQuell Therapeutics Limited
- RECRUITINGPHASE1, PHASE2NCT06947473Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.Beijing GoBroad Hospital
- RECRUITINGPHASE2NCT05029336Autologous Stem Cell Transplant (ASCT) for Autoimmune DiseasesStephan Grupp MD PhD
- RECRUITINGPHASE2NCT07047690A Study of Nemolizumab for the Treatment of Adults With Systemic SclerosisGalderma R&D
- RECRUITINGPHASE2NCT07287670EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)Mediar Therapeutics
- RECRUITINGNCT07256418Transcriptomic Study of Cutaneous Fibroblasts in SclerodermaCentre Hospitalier Universitaire Dijon
- RECRUITINGPHASE1NCT07295847A Study of AZD0120 in Autoimmune DiseasesAstraZeneca
- RECRUITINGNANCT07292961Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With SclerodermaHacettepe University